Haines Donovan C, Chen Baozhi, Tomchick Diana R, Bondlela Muralidhar, Hegde Amita, Machius Mischa, Peterson Julian A
Department of Chemistry, The University of Texas at Dallas, Dallas, Texas 75083-0688, USA.
Biochemistry. 2008 Mar 25;47(12):3662-70. doi: 10.1021/bi7023964. Epub 2008 Feb 26.
P450BM-3 is an extensively studied P450 cytochrome that is naturally fused to a cytochrome P450 reductase domain. Crystal structures of the heme domain of this enzyme have previously generated many insights into features of P450 structure, substrate binding specificity, and conformational changes that occur on substrate binding. Although many P450s are inhibited by imidazole, this compound does not effectively inhibit P450BM-3. Omega-imidazolyl fatty acids have previously been found to be weak inhibitors of the enzyme and show some unusual cooperativity with the substrate lauric acid. We set out to improve the properties of these inhibitors by attaching the omega-imidazolyl fatty acid to the nitrogen of an amino acid group, a tactic that we used previously to increase the potency of substrates. The resulting inhibitors were significantly more potent than their parent compounds lacking the amino acid group. A crystal structure of one of the new inhibitors bound to the heme domain of P450BM-3 reveals that the mode of interaction of the amino acid group with the enzyme is different from that previously observed for acyl amino acid substrates. Further, required movements of residues in the active site to accommodate the imidazole group provide an explanation for the low affinity of imidazole itself. Finally, the previously observed cooperativity with lauric acid is explained by a surprisingly open substrate-access channel lined with hydrophobic residues that could potentially accommodate lauric acid in addition to the inhibitor itself.
P450BM-3是一种经过广泛研究的细胞色素P450,它天然地与细胞色素P450还原酶结构域融合。该酶血红素结构域的晶体结构先前已为P450结构、底物结合特异性以及底物结合时发生的构象变化等特征提供了许多见解。尽管许多细胞色素P450会被咪唑抑制,但这种化合物并不能有效抑制P450BM-3。先前已发现ω-咪唑基脂肪酸是该酶的弱抑制剂,并与底物月桂酸表现出一些不寻常的协同作用。我们着手通过将ω-咪唑基脂肪酸连接到氨基酸基团的氮原子上来改善这些抑制剂的性能,我们之前曾采用这种策略来提高底物的效力。所得抑制剂的效力明显高于其不含氨基酸基团的母体化合物。一种与P450BM-3血红素结构域结合的新型抑制剂的晶体结构表明,氨基酸基团与该酶的相互作用模式不同于先前观察到的酰基氨基酸底物的相互作用模式。此外,活性位点中残基为容纳咪唑基团所需的移动为咪唑本身的低亲和力提供了解释。最后,先前观察到的与月桂酸的协同作用可以通过一个令人惊讶的开放底物通道来解释,该通道内衬有疏水残基,除了抑制剂本身外,还可能容纳月桂酸。